Rhythm acquires Dutch biotech company Xinvento
Rhythm Pharmaceuticals’ subsidiary Rhythm Pharmaceuticals Netherlands has purchased Dutch biotech company Xinvento and its portfolio of investigational therapeutics. Under the...
Rhythm Pharmaceuticals’ subsidiary Rhythm Pharmaceuticals Netherlands has purchased Dutch biotech company Xinvento and its portfolio of investigational therapeutics. Under the...
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
Tobacco giant Philip Morris now generates around a quarter of its $28bn sales revenue from smoke-free products and aims to boost this share to more than half by 2025 under...
US real estate investment company Harrison Street and UK real estate group Trinity Investment Management this week announced their joint acquisition of Nottingham-based science business incubator BioCity. The £120m deal...
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review.
Within nine months of closing a $60m Series C round, Oxford-headquartered artificial intelligence (AI) drug discovery company Exscientia has raised an additional $100m in a new Series C financing. This...
US-headquartered pharma giant Merck has entered into a definitive agreement to acquire autoimmune-focused Pandion Therapeutics. The deal is priced at $60 per share in cash, which represents a total value...
Seattle-based pre-clinical biotech Umoja Biopharma aims to revolutionise immunotherapy by retooling the patient’s immune system in vivo. Based on the pioneering work of Seattle Children’s Research Institute and Purdue University,...
Precision immunology company ImmuneID has launched with $17m in funding. The financing round was led by founding investor Longwood Fund; other investors participating in the round include XFund and Arch...
Precision medicine-focused Gemini Therapeutics has completed a business combination transaction with Foresite Capital’s special purpose acquisition company (SPAC) FS Development Corp (FSDC).
Belgium-based Imcyse has closed a €21.3m ($25.8m) Series B round. Investors participating in the round included Société Fédérale de Participations et d'Investissement (SFPI), Biogenosis and Katholieke Universiteit Leuven (KUL), the...